Ensysce Biosciences Presenting at Upcoming Meetings
Ensysce Biosciences (NASDAQ:ENSC) has announced its participation in two upcoming meetings in October 2024. At the Society for Neuroscience meeting on October 5, new data will be presented on their Opioid Use Disorder (OUD) program, showcasing a study on methadone's effects in a modified rat model of physical dependence. This research, conducted with Sygnature Discovery, aims to develop novel methadone analogues with reduced cardiovascular side effects and abuse potential using Ensysce's Trypsin Activated Abuse Protection (TAAP) technology.
On October 16, Ensysce's CEO, Dr. Lynn Kirkpatrick, will present at the Formulation & Delivery US 2024 meeting, discussing their TAAP and MPAR platforms and highlighting their lead products, PF614 and PF614-MPAR. These products have received Fast Track and Breakthrough Therapy designations from the FDA, demonstrating their unique approach to delivering effective drugs more safely and efficiently.
Ensysce Biosciences (NASDAQ:ENSC) ha annunciato la sua partecipazione a due eventi che si terranno a ottobre 2024. Al convegno della Society for Neuroscience del 5 ottobre, verranno presentati nuovi dati sul loro programma per il Disturbo da Uso di Oppioidi (OUD), mostrando uno studio sugli effetti della metadone in un modello di ratto modificato per la dipendenza fisica. Questa ricerca, condotta con Sygnature Discovery, mira a sviluppare nuovi analoghi della metadone con effetti collaterali cardiovascolari ridotti e minore potenziale di abuso, utilizzando la tecnologia Trypsin Activated Abuse Protection (TAAP) di Ensysce.
Il 16 ottobre, il CEO di Ensysce, Dr. Lynn Kirkpatrick, presenterà al convegno Formulation & Delivery US 2024, discutendo delle loro piattaforme TAAP e MPAR e mettendo in evidenza i loro prodotti di punta, PF614 e PF614-MPAR. Questi prodotti hanno ricevuto le designazioni Fast Track e Breakthrough Therapy dalla FDA, dimostrando il loro approccio unico per somministrare farmaci efficaci in modo più sicuro ed efficiente.
Ensysce Biosciences (NASDAQ:ENSC) ha anunciado su participación en dos reuniones que tendrán lugar en octubre de 2024. En la reunión de la Society for Neuroscience el 5 de octubre, se presentarán nuevos datos sobre su programa para el Trastorno por Uso de Opioides (OUD), mostrando un estudio sobre los efectos de la metadona en un modelo de rata modificado para la dependencia física. Esta investigación, realizada con Sygnature Discovery, tiene como objetivo desarrollar nuevos análogos de metadona con efectos secundarios cardiovasculares reducidos y menor potencial de abuso utilizando la tecnología Trypsin Activated Abuse Protection (TAAP) de Ensysce.
El 16 de octubre, el CEO de Ensysce, Dr. Lynn Kirkpatrick, presentará en la reunión Formulation & Delivery US 2024, discutiendo sus plataformas TAAP y MPAR y destacando sus productos líderes, PF614 y PF614-MPAR. Estos productos han recibido las designaciones Fast Track y Breakthrough Therapy de la FDA, lo que demuestra su enfoque único para administrar medicamentos efectivos de manera más segura y eficiente.
Ensysce Biosciences (NASDAQ:ENSC)은 2024년 10월에 열리는 두 개의 회의에 참여한다고 발표했습니다. 10월 5일 신경과학회에서, 그들의 오피오이드 사용 장애(OUD) 프로그램에 대한 새로운 데이터를 발표하고, 물리적 의존성을 가진 수정된 쥐 모델에서 메타돈의 효과에 대한 연구를 보여줄 예정입니다. 이 연구는 Sygnature Discovery와 협력하여 수행되었으며, Ensysce의 트립신 활성화 남용 방지(TAAP) 기술를 사용하여 심혈관 부작용과 남용 가능성이 감소된 신규 메타돈 유사체를 개발하는 것을 목표로 하고 있습니다.
10월 16일, Ensysce의 CEO인 Dr. Lynn Kirkpatrick은 Formulation & Delivery US 2024 회의에서 발표하며, TAAP 및 MPAR 플랫폼에 대해 논의하고 그들의 주요 제품인 PF614 및 PF614-MPAR을 강조할 것입니다. 이 제품들은 FDA로부터 패스트 트랙 및 혁신 의약품으로 지정되어, 더 안전하고 효율적으로 효과적인 약물을 전달하는 독특한 접근 방식을 보여줍니다.
Ensysce Biosciences (NASDAQ:ENSC) a annoncé sa participation à deux réunions à venir en octobre 2024. Lors de la réunion de la Society for Neuroscience le 5 octobre, de nouvelles données seront présentées sur leur programme de trouble d'utilisation des opioïdes (OUD), mettant en lumière une étude sur les effets de la méthadone dans un modèle de rat modifié pour la dépendance physique. Cette recherche, menée en collaboration avec Sygnature Discovery, vise à développer de nouveaux analogues de méthadone avec des effets secondaires cardiovasculaires réduits et un potentiel d'abus moindre en utilisant la technologie Trypsin Activated Abuse Protection (TAAP) d'Ensysce.
Le 16 octobre, le PDG d'Ensysce, Dr. Lynn Kirkpatrick, présentera lors de la réunion Formulation & Delivery US 2024, discutant de leurs plateformes TAAP et MPAR et mettant en avant leurs produits phares, PF614 et PF614-MPAR. Ces produits ont reçu des désignations Fast Track et Breakthrough Therapy de la FDA, témoignant de leur approche unique pour délivrer des médicaments efficaces de manière plus sûre et efficace.
Ensysce Biosciences (NASDAQ:ENSC) hat seine Teilnahme an zwei bevorstehenden Treffen im Oktober 2024 angekündigt. Auf dem Treffen der Society for Neuroscience am 5. Oktober werden neue Daten zu ihrem Programm für die Opioidabhängigkeit (OUD) vorgestellt, die eine Studie über die Wirkung von Methadon in einem modifizierten Rattenmodell der physischen Abhängigkeit zeigen. Diese Forschung, die in Zusammenarbeit mit Sygnature Discovery durchgeführt wurde, zielt darauf ab, neuartige Methadonanaloga mit reduzierten kardiovaskulären Nebenwirkungen und Missbrauchspotenzial zu entwickeln, wobei die Trypsin Activated Abuse Protection (TAAP) Technologie von Ensysce eingesetzt wird.
Am 16. Oktober wird der CEO von Ensysce, Dr. Lynn Kirkpatrick, auf dem Formulation & Delivery US 2024 Treffen präsentieren, wo er über ihre TAAP- und MPAR-Plattformen sprechen und ihre Hauptprodukte, PF614 und PF614-MPAR, hervorheben wird. Diese Produkte haben von der FDA die Auszeichnung Fast Track und Breakthrough Therapy erhalten, was ihren einzigartigen Ansatz zur sichereren und effizienteren Bereitstellung von wirksamen Arzneimitteln zeigt.
- Presentation of new data on Opioid Use Disorder program at Society for Neuroscience meeting
- CEO invited as Expert Speaker at Formulation & Delivery US 2024 meeting
- Development of novel methadone analogues with potential for reduced side effects and abuse
- Fast Track and Breakthrough Therapy designations from FDA for lead products PF614 and PF614-MPAR
- None.
~ New Data on Opioid Use Disorder Program at Society for Neuroscience Meeting ~
~ Ensysce CEO Invited Expert Speaker at Formulation & Delivery US 2024 Meeting ~
SAN DIEGO, CA / ACCESSWIRE / September 24, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced its participation in two upcoming meetings in October 2024.
October 5, 2024: New data will be presented in a poster session in collaboration with Sygnature Discovery at the Society for Neuroscience meeting in Chicago in the session for Addictive Drugs: Drug Tolerance, Dependence, and Toxicity.The poster entitled "Methadone ameliorates the effects of morphine withdrawal in a modified rat model of physical dependence" is the first study of its kind in a pre-clinical model to evaluate the efficacy of novel agents for treating Opioid Use Disorder (OUD).OUD affects 16 million people worldwide and can be attributed to 500,000 deaths each year. OUD is characterized by intense cravings for opioids and severe withdrawal effects if an opioid cannot be found. Methadone is a common agent used to reduce these cravings yet can be abused. OUD has unwanted cardiovascular side effects and due to varied pharmacology can lead to overdose and death. Ensysce has been applying its Trypsin Activated Abuse Protection (TAAP) technology to develop novel methadone analogues with reduced cardiovascular side effects and reduced abuse potential. Sygnature Discovery employs relevant rodent models, knowledge about applicable and sensitive endpoints, and state-of-the-art technologies in the assessment of behavioral effects of novel drug candidates.
October 16, 2024: Dr. Lynn Kirkpatrick, CEO of Ensysce, has been invited as an Expert Speaker at the Formulation & Delivery US 2024 meeting in San Diego, CA to present "TAAP and MPAR - Delivering Prescription Drugs Safely with Added Oral Overdose Protection". The presentation will highlight the versatility of the TAAP and MPAR platforms, and showcase Ensysce's lead products, PF614 and PF614-MPAR. The Fast Track and Breakthrough Therapy designations from the FDA demonstrate the uniqueness of these approaches to deliver effective drugs more safely and efficiently.
https://www.linkedin.com/showcase/formulation-delivery-og - Formulation & Delivery by Oxford Global
Dr. Kirkpatrick said, "The research Ensysce is conducting with Sygnature Discovery is just one demonstration of how the TAAP program can improve an existing effective agent, with the intent of making it safer and improving quality of life. We believe our chemical approach to improve drugs to treat pain, ADHD or OUD will positively impact health and wellbeing."
About Ensysce Biosciences
Ensysce Biosciences is a clinical-stage company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.
Forward-Looking Statements
Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.
Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196
Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us
SOURCE: Ensysce Biosciences Inc.
View the original press release on accesswire.com
FAQ
What will Ensysce Biosciences (ENSC) present at the Society for Neuroscience meeting in October 2024?
What technology is Ensysce Biosciences (ENSC) using to develop novel methadone analogues?
What will Dr. Lynn Kirkpatrick, CEO of Ensysce Biosciences (ENSC), present at the Formulation & Delivery US 2024 meeting?